B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse

Immunity
Tsvetelina Pentcheva-HoangJames P Allison

Abstract

The reported affinity differences between CD28 and CTLA-4 binding to B7-1 and B7-2 may serve to selectively regulate CD28 and CTLA-4 function by differentially recruiting and/or stabilizing these molecules at the immunological synapse. Here we show that ligand binding is important for the accumulation of both CD28 and CTLA-4 at the synapse. While CD28 is recruited to the synapse in the absence of B7-1 and B7-2 binding, it is not effectively stabilized there, as its localization can be disrupted by CTLA-4. In the case of CTLA-4, ligand binding is critical for its concentration at the synapse. We also demonstrate that the affinity and avidity differences in ligand binding translate into selective recruitment of CD28 or CTLA-4 to the immunological synapse--B7-1 is the major ligand mediating CTLA-4 localization, while B7-2 is the main ligand for CD28 concentration at the synapse.

References

Dec 1, 1992·The Journal of Experimental Medicine·P S LinsleyN K Damle
Jun 15, 1990·Science·R H Schwartz
Jul 16, 1987·Nature·J F BrunetP Golstein
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·D J LenschowJ A Bluestone
Aug 1, 1994·The Journal of Experimental Medicine·K S HathcockR J Hodes
Aug 1, 1996·Human Gene Therapy·T M Kinsella, G P Nolan
Oct 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·M S KuhnsJ P Allison
Nov 20, 2001·Nature Immunology·S K BromleyM L Dustin
Aug 28, 2002·Immunity·Alison V CollinsSimon J Davis
Feb 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Xuewu ZhangStanley G Nathenson
Dec 4, 2003·Nature Reviews. Immunology·Oreste Acuto, Frédérique Michel

❮ Previous
Next ❯

Citations

Jan 24, 2007·Cancer Immunology, Immunotherapy : CII·Juliana IdoyagaLaura Bonifaz
Feb 10, 2009·Cancer Immunology, Immunotherapy : CII·Jeffrey Weber
Jul 8, 2010·Cancer Immunology, Immunotherapy : CII·Juan DubrotIgnacio Melero
Jun 10, 2009·Digestive Diseases and Sciences·James D LordGeorge B McDonald
Aug 21, 2009·Journal of Clinical Immunology·Weiyan WangJianhua Zhu
Apr 23, 2013·Human Immunology·Jaclyn Stromp PerainoZhirui Wang
Feb 11, 2010·European Journal of Human Genetics : EJHG·Volker RuppertUNKNOWN German Heart Failure Network
Jun 21, 2013·Nature Communications·Yuwen ZhuLieping Chen
Jul 9, 2011·Nature Immunology·E John Wherry
Oct 22, 2004·Nature Immunology·Eric C Logue, William C Sha
Dec 8, 2004·Nature Medicine·Ronald N Germain
Apr 26, 2007·Nature Reviews. Immunology·Laurent Coscoy
Jan 26, 2008·Nature Reviews. Immunology·Christopher E Rudd
Jan 18, 2006·Cell Death and Differentiation·M L Schmitz, D Krappmann
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Diana A Alvarez AriasHarvey Cantor
Jun 30, 2012·Proceedings of the National Academy of Sciences of the United States of America·James E D ThaventhiranDouglas T Fearon
May 30, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ruihua ZhaoXingxing Zang
Dec 16, 2010·The Journal of Biological Chemistry·Chao YuSimon J Davis
Apr 25, 2007·The Journal of Experimental Medicine·Leslie E Summers-DeLucaJennifer L Gommerman
Feb 27, 2009·Antioxidants & Redox Signaling·David K StoneHoward E Gendelman
Apr 7, 2007·Human Gene Therapy·Jianzheng YangShuzheng Liu
Feb 10, 2012·Hybridoma·Patcharee RitprajakMiyuki Azuma
Aug 21, 2009·International Immunology·Shen-An Hwang, Jeffrey K Actor
Jan 13, 2006·Immunology and Cell Biology·Axel J HueberThomas Nagel
Dec 9, 2009·Annual Review of Immunology·David R FooksmanMichael L Dustin
Mar 23, 2006·Annual Review of Immunology·Wendy A TeftJoaquín Madrenas
Sep 5, 2012·The Journal of Clinical Investigation·Maria Grazia RuoccoSandra Demaria
Sep 24, 2004·Arthritis Research & Therapy·P'ng Loke, James P Allison
Jun 18, 2005·Genome Biology·Mary CollinsBeatriz M Carreno
Nov 7, 2009·Journal of Leukocyte Biology·Takayoshi OwadaHiroshi Nakajima
Mar 4, 2014·PloS One·Mariano Sanchez-LockhartJim Miller
Oct 16, 2012·Current Pharmaceutical Design·Jennifer P Chou, Rita B Effros
Sep 4, 2013·Clinical & Developmental Immunology·Nien Yee Kow, Anselm Mak
Aug 30, 2005·Proceedings of the National Academy of Sciences of the United States of America·Helga SchneiderChristopher E Rudd
Oct 31, 2007·Proceedings of the National Academy of Sciences of the United States of America·Tsvetelina Pentcheva-HoangJames P Allison

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.